Drugs / NY-ESO-1 TCR/ dnTGFβRII
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07389239 | Jun 2026 → Dec 2031 expected | ovarian cancer | University of Chicago | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 TCR/ dnTGFβRII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07389239 ↗ |
| Modality | Cell therapy | “gene-modified T cells” NCT07389239 ↗ |